Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05776342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

Study acronym: CANOPE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 7 more changesShow less
    • Primary completion date: Aug 2030 to Dec 31, 2030
    • Study completion date: Aug 2031 to Dec 31, 2031
    • Start date changed from estimate of Apr 30, 2023 to Jan 1, 2003
    • Secondary endpoints revised (7)
    • Study description expanded, about 88 words
    • Site details revised at 15 of 15 sites
    • Study title shortened, about 1 word
  3. Start date: Mar 30, 2023 to Apr 30, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.
Trial Details
NCT Number NCT05776342
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma
Enrollment 4,050 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov